[{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kyowa Kirin Terminates ASACOL\u00ae deal with Zeria Pharmaceutical","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$130.3 million","upfrontCash":"Undisclosed","newsHeadline":"Astellas Transfers Dificlir in Europe, Middle East, Africa and selected CIS to Tillotts Pharma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tillotts Pharma AG Continues Growth With Launch In Belgium, The Netherlands And Luxembourg","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tillotts Pharma AG Announces That Dificlirtm (fidaxomicin) Is Recommended For The Treatment Of Clostridioides Difficile Infection (CDI) By Escmid","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals by Zeria Pharmaceutical
DIFICLIR (fidaxomicin) is a macrolide antibacterial medicine indicated as an initial treatment and first recurrence of Clostridioides difficile infection. Fidaxomicin treats CDI with minimal disruption to the microbiota, helping to preserve colonisation resistance.
Dificlir is an anti-toxin which contains the dynamic substance fidaxomicin used for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients.
Under the agreement, Astellas Europe will transfer its marketing authorizations for Dificlirtm (generic name: fidaxomicin) tablets for Clostridium difficile infections in Europe, Middle East, Africa and selected Commonwealth of Independent States to Tillotts.
Kyowa Kirin will finish its commercialization activity for ASACOL on March 31, 2020, and Zeria will obtain the full rights of the commercialization activities for ASACOL from April 1, 2020.